Plus Therapeutics (PSTV) Earnings Date, Estimates & Call Transcripts $0.64 -0.02 (-2.46%) As of 11:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Plus Therapeutics Earnings Summary Upcoming Earnings DateMay. 13After Market ClosesEstimatedConsensus EPS (Mar. 27) -$0.51 Actual EPS (Mar. 27) -$0.67 Missed By -$0.16 Actual Revenue (Mar. 27) $1.80MPlus Therapeutics posted Q4 2024 earnings on March 27, 2025, reporting an EPS of -$0.67, which missed the consensus estimate of -$0.51 by $0.16. Quarterly revenue was reported to be $1.80 million, above analyst estimates of $1.19 million. With a trailing EPS of -$2.50, Plus Therapeutics' earnings are expected to grow next year, from ($2.30) to ($1.60) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings ReportConference Call Transcript & Audio Report Press Release (8-K) Annual Report (10-K)PSTV Upcoming EarningsPlus Therapeutics' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules. Powered by Get Plus Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataPSTV Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.PSTV Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Plus Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.30-$0.30-$0.30Q2 20251-$0.32-$0.32-$0.32Q3 20251-$0.35-$0.35-$0.35Q4 20251-$0.58-$0.58-$0.58FY 20254($1.55)($1.55)($1.55) Remove Ads Plus Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/13/2025(Estimated)--------3/27/2025Q4 2024-$0.51-$0.67 -$0.16-$0.67$1.19M$1.80M8/14/2024Q2 2024--$0.71 -$0.71-$0.71-$1.28M5/15/2024Q1 2024-$1.09-$0.75+$0.34-$0.75-$1.68M3/5/2024Q4 2023-$0.78-$0.70+$0.08-$0.70$1.26M$1.31M10/31/2023Q3 2023-$0.58-$1.00 -$0.42-$1.00$1.87M$1.24M8/14/2023Q2 2023-$1.91-$0.59+$1.32-$0.59$0.80M$1.85M4/20/2023Q1 2023-$2.10-$2.10--$0.14$0.30M$0.51M Plus Therapeutics Earnings - Frequently Asked Questions When is Plus Therapeutics's earnings date? Plus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based off last year's report dates. Learn more on PSTV's earnings history. Did Plus Therapeutics beat their earnings estimates last quarter? In the previous quarter, Plus Therapeutics (NASDAQ:PSTV) missed the analysts' consensus estimate of ($0.51) by $0.16 with a reported earnings per share (EPS) of ($0.67). Learn more on analysts' earnings estimate vs. PSTV's actual earnings. How can I listen to Plus Therapeutics's earnings conference call? The conference call for Plus Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Plus Therapeutics's conference call transcript? The conference call transcript for Plus Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Plus Therapeutics generate each year? Plus Therapeutics (NASDAQ:PSTV) has a recorded annual revenue of $4.91 million. How much profit does Plus Therapeutics generate each year? Plus Therapeutics (NASDAQ:PSTV) has a recorded net income of -$13.32 million. PSTV has generated -$2.50 earnings per share over the last four quarters. What is Plus Therapeutics's EPS forecast for next year? Plus Therapeutics's earnings are expected to grow from ($2.30) per share to ($1.60) per share in the next year. More Earnings Resources from MarketBeat Related Companies Beyond Air Earnings Results QT Imaging Earnings Results Vivos Therapeutics Earnings Results ReWalk Robotics Earnings Results PetVivo Earnings Results IRIDEX Earnings Results NeuroOne Medical Technologies Earnings Results Allurion Technologies Earnings Results NeurAxis Earnings Results SeaStar Medical Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s Next Remove Ads This page (NASDAQ:PSTV) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
